Dr. Jonathan Trent on FDA Approval of Trabectedin for Soft Tissue Sarcomas
14 意见
• 07/18/23
0
0
嵌入
Jonathan C. Trent, MD, professor of Medicine, co-director, Musculoskeletal Center, Sarcoma Medical Research Program, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the FDA approval of trabectedin for patients with soft tissue sarcomas.
显示更多
脸书评论
SORT BY-
热门评论
-
最新评论